CTS-Clinical and Translational Science

Papers
(The H4-Index of CTS-Clinical and Translational Science is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Issue Information300
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer135
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications100
Expression of Concern:Zhou, Y., & Zhou, J.Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and 66
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine62
Issue Information62
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry55
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study53
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community47
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study46
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index45
Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets44
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach42
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue41
Pharmacogenomic landscape of Indian population using whole genomes37
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization37
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin36
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts35
Expanding regulatory science: Regulatory complementarity and reliance35
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker34
Using partition analysis as a facile method to derive net clearances29
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists29
Intradermal substance P as a challenge agent in healthy individuals29
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data28
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection28
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units26
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document26
First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome26
Generalizability in real‐world trials26
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis26
Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?26
0.064658164978027